222. 一次性ネフローゼ症候群 Primary nephrotic syndrome Clinical trials / Disease details
臨床試験数 : 310 / 薬物数 : 295 - (DrugBank : 117) / 標的遺伝子数 : 63 - 標的パスウェイ数 : 194
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ITMCTR2200005709 | 2021-07-01 | 2021-07-06 | Efficacy and Safety of Tripterygium Wilfordii Multiglycosides in Idiopathic Membranous Nephropathy: Protocol for An Open-label Randomized Controlled Clinical Trial | Efficacy and Safety of Tripterygium Wilfordii Multiglycosides in Idiopathic Membranous Nephropathy: Protocol for An Open-label Randomized Controlled Clinical Trial | Idiopathic membranous nephropathy | Experimental group:On the basis of ACEI/ARB, tripterygium wilfordii polyglycoside tablets were added;Control group:The original dose of ACEI/ARB was used for treatment; | Department of Nephrology, Sichuan Provincial People's Hospital | NULL | Recruiting | 18 | 65 | Both | Experimental group:18;Control group:18; | N/A | China |
| 2 | ChiCTR2100048382 | 2021-07-01 | 2021-07-06 | Efficacy and Safety of Tripterygium Wilfordii Multiglycosides in Idiopathic Membranous Nephropathy: Protocol for An Open-label Randomized Controlled Clinical Trial | Efficacy and Safety of Tripterygium Wilfordii Multiglycosides in Idiopathic Membranous Nephropathy: Protocol for An Open-label Randomized Controlled Clinical Trial | Idiopathic membranous nephropathy | Experimental group:On the basis of ACEI/ARB, tripterygium wilfordii polyglycoside tablets were added;Control group:The original dose of ACEI/ARB was used for treatment; | Department of Nephrology, Sichuan Provincial People's Hospital | NULL | Recruiting | 18 | 65 | Both | Experimental group:18;Control group:18; | N/A | China |
| 3 | ChiCTR2000037467 | 2020-12-31 | 2020-08-28 | Effect of Tripterygium wilfordii polyglycoside tablets on the inhibition of TM on complement pathway and related inflammatory markers in membranous nephropathy | The complement pathway and related inflammatory factor markers in the treatment of idiopathic membranous nephropathy | idiopathic membranous nephropathy | Gold Standard:Cell hemolysis test;Index test:Immunochemiluminescence (ECL) and flow cytometry (FCM) were used to determine the activity of each complement pathway and the target of complement; Complement hemolysis test is usually used to determine the activity of total complement and single complement component, but it is difficult to be applied to clinical ; | Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine | NULL | Pending | 18 | 80 | Both | Target condition:40;Difficult condition:40 | China | |
| 4 | NCT01161459 (ClinicalTrials.gov) | June 2010 | 12/7/2010 | Treatment of Idiopathic Membranous Nephropathy With Tripterygium Wilfordii Plus Steroid vs Tacrolimus Plus Steroid | Research Institute of Nephrology, Jinling Hospital | Idiopathic Membranous Nephropathy | Drug: Tripterygium wilfordii;Drug: FK506 | Zhi-Hong Liu, M.D. | NULL | Completed | 18 Years | 65 Years | Both | 100 | N/A | China |
| 5 | NCT00801463 (ClinicalTrials.gov) | January 2009 | 2/12/2008 | Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis | Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis | Proteinuria;Focal Segmental Glomerulosclerosis | Drug: tripterygium wilfordii (TW) | Nanjing University School of Medicine | NULL | Completed | 18 Years | 60 Years | Both | 67 | N/A | China |
| 6 | NCT00518219 (ClinicalTrials.gov) | July 2007 | 16/8/2007 | To Compare the Efficacy and Safety of Tripterygium Wilfordii (TW) Versus Valsartan in the Membranous Nephropathy (MN) | To Compare the Efficacy and Safety of TW vs Valsartan in the MN | Membranous Nephropathy | Drug: TW | Nanjing University School of Medicine | NULL | Completed | 18 Years | 65 Years | Both | 68 | Phase 4 | China |